National Pension Service Increases Stock Holdings in DexCom, Inc. $DXCM

Key Points

• National Pension Service increased its DexCom stake by 3.9% in the second quarter, bringing its holdings to 660,309 shares valued at approximately $44.5 million. Institutional investors and hedge funds collectively own 97.75% of DXCM.
• DexCom reported quarterly earnings of $0.70 per share, exceeding estimates of $0.61, while revenue rose 13.1% year over year to $1.31 billion.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $88.71; meanwhile, company insiders sold 65,777 shares worth roughly $5.0 million over the past 90 days.

National Pension Service boosted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 660,309 shares of the medical device company's stock after acquiring an additional 24,756 shares during the quarter. National Pension Service owned 0.17% of DexCom worth $44,472,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Plato Investment Management Ltd acquired a new position in shares of DexCom during the 2nd quarter worth about $782,000. Aurora Investment Counsel acquired a new stake in DexCom in the 2nd quarter worth about $2,340,000. E Fund Management Co. Ltd. acquired a new stake in DexCom in the 2nd quarter worth about $1,273,000. SWS Partners purchased a new stake in DexCom during the 2nd quarter worth approximately $2,896,000. Finally, Silvant Capital Management LLC purchased a new stake in DexCom during the 2nd quarter worth approximately $5,359,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Down 1.8%

DXCM stock opened at $83.03 on Friday. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The firm has a market cap of $31.33 billion, a PE ratio of 32.82, a PEG ratio of 1.39 and a beta of 1.42. The firm's 50 day moving average price is $82.75 and its 200-day moving average price is $72.80. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the prior year, the business posted $0.48 earnings per share. The firm's revenue for the quarter was up 13.1% compared to the same quarter last year. On average, equities research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on DXCM. Benchmark raised their target price on DexCom from $77.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Robert W. Baird set a $105.00 price target on DexCom in a research report on Friday, July 31st. Citigroup reissued a "buy" rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Argus raised their price objective on DexCom from $86.00 to $96.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Finally, BTIG Research restated a "buy" rating and issued a $90.00 price objective (up from $80.00) on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $88.71.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 2,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares of the company's stock, valued at $4,168,052.64. This trade represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares of the company's stock, valued at approximately $25,106,990.40. This trade represents a 7.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,777 shares of company stock valued at $4,950,714 over the last 90 days. Company insiders own 0.28% of the company's stock.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.